Multiple endocrine neoplasia type 1 future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
* Role of surgery for non functioning pancreatic [[neuroendocrine tumor]]s is also under investigation. | * Role of surgery for non functioning pancreatic [[neuroendocrine tumor]]s is also under investigation. | ||
* The interaction between menin and mixed lineage [[leukemia]] [[protein]] 1(MLL1) also known as a [[histone]] H3 [[lysine]] 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1 | * The interaction between menin and mixed lineage [[leukemia]] [[protein]] 1(MLL1) also known as a [[histone]] H3 [[lysine]] 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1 | ||
* | * Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1. | ||
* Molecular | * Molecular phenotyping of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage. | ||
==Reference== | ==Reference== | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:Hereditary cancers]] | [[Category:Hereditary cancers]] |
Revision as of 04:54, 14 September 2015
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 future or investigational therapies On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies |
FDA on Multiple endocrine neoplasia type 1 future or investigational therapies |
CDC on Multiple endocrine neoplasia type 1 future or investigational therapies |
Multiple endocrine neoplasia type 1 future or investigational therapies in the news |
Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
Future or Investigational Therapies
- Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
- National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
- Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
- mTOR inhibitors for pancreatic neuroendocrine tumors are other subjects undergoing investigation.
- Role of surgery for non functioning pancreatic neuroendocrine tumors is also under investigation.
- The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1
- Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
- Molecular phenotyping of tumors have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.
Reference
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check
|pmid=
value (help).